1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Global Breast Cancer Predictive Genetic Testing Market Outlook 2022

Global Breast Cancer Predictive Genetic Testing Market Outlook 2022

  • April 2017
  • 140 pages
  • ID: 4825304
  • Format: PDF
  • By Kuick Research

Summary

Table of Contents

“Global Breast Cancer Predictive Genetic Testing Market Outlook 2022” report analyzes the various aspects related to the emergence and development of breast cancer genetic test market across the globe.

The current and future aspects of cancer genomics have covered a long path of advances and the journey is still ongoing.

The technological improvements in genomic sciences had allowed parallel sequencing of both tumors and germline mutations and had provided the weapon of next generation sequencing. Under the supervision of intellectual property laws and appropriate guidelines cancer susceptibility testing has become one of the major assets in medical practice. There appears to be pervasive belief in both scientific and public circles that genetic testing is going to be the cornerstone of much, if not all, of what medicine holds for the future. Besides, what is generally meant is the wide scale testing for susceptibility to common diseases especially for cancer and for responsiveness to drugs has come to be described as genetic profiling.

With the knowledge and acceptance of the fact that the breast cancer is on alarming scale, the major concern has been diverted towards this scenario. As there are 5% to 10% of breasts cancer cases which occur due to the germline mutations and the most common ones are the BRCA1 and BRCA2 mutations. Fortunately, these hereditary cancers can be prevented if diagnosed early or even before its occurrence which includes the susceptibility testing of breast cancer genes.

Breast cancer susceptibility has been in existence since 1966 and had served as the boon for the patients as well as the stakeholders. Certainly, 2013 have been the year of major events in the field of predictive genetic testing as US FDA approved the use of next generation DNA sequencing in clinical practice. Further, the decision of Supreme Court invalidated the BRCA patent held by Myriad genetics. These decisions made the new entries and embraced the competitions in the cancer genetics market.

Leading to the current scenario which is completely changing and the market is now subjected to the direct to consumer BRCA testing kits provided by varied pharmaceuticals. However, the new entrants to the global market will face considerable challenges in persuading physicians to choose them as a test provider. New entrants will need to provide indication of subsequent in meeting the requirements of physicians such as reputation, trust, transparency, and counseling. Some of these aspects cannot be established quickly, and take time to establish.

The future holds up for the precision medicine and cancer predictability will be proving a great deal, as through the aid of breast cancer predictive testing and better counseling measures this regimen can turn out into an effective prophylactic modality for hereditary as well as early stage breast cancer.

The predictive risk calculations will be leading towards the better management and improved survival rates. Over the next decade or two, it seems likely that the technology will screen entire populations or specific subgroups for genetic information in order to target interventions to individual patients that will improve their health and prevent disease. While the evidence base is still growing, genetic services industry leaders strongly believe that emerging testing capabilities will have significant clinical impact in the future.

“Global Breast Cancer Predictive Genetic Testing Market Outlook 2022” Report Highlights:
• Hereditary Breast Cancer Genes
• Conceptual of Breast Cancer Susceptibility
• Predictive Cancer Testing Essentials
• Economical, Ethical & Social Aspects
• Global Prevalence of Breast Cancer
• Market & Cost Analysis of Predictive Testing
• Insurance Affairs for Breast Cancer Predictive Testing

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
North America Cancer Tissue Diagnostics Market to 2027 - Regional Analysis and Forecasts by Test Type and Country

North America Cancer Tissue Diagnostics Market to 2027 - Regional Analysis and Forecasts by Test Type and Country

  • $ 3000
  • August 2019

The North America cancer tissue diagnostics market is expected to reach US$ 1,587.38 Mn in 2027 from US$ 923.79 Mn in 2018. This market is projected to grow at a growth rate of 6.5% from 2019-2027.The ...

Mucin 1 - Pipeline Review, H2 2019

Mucin 1 - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Mucin 1 - Pipeline Review, H2 2019SummaryMucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial ...

GLOBAL LIQUID BIOPSY MARKET FORECAST 2019-2027

GLOBAL LIQUID BIOPSY MARKET FORECAST 2019-2027

  • $ 2500
  • September 2019

KEY FINDINGSDevelopments in precision medicines, increasing prevalence of cancer cases in the elderly population, and supportive government initiatives are some of the factors that are contributing to ...


ref:plp2017

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on